The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management

Europace

Volumn 11, Issue 4, 2009, Pages 423-434

  Nabauer, Michael ^a   Gerth, Andrea ^a   Limbourg, Tobias ^b   Schneider, Steffen ^b   Oeff, Michael ^c   Kirchhof, Paulus ^d   Goette, Andreas ^e   Lewalter, Thorsten ^f   Ravens, Ursula ^g   Meinertz, Thomas ^h   Breithardt, Günter ^d   Steinbeck, Gerhard ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Municipal Hospital   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; German AFNET Registry; Guidelines; Rate control; Rhythm control

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN II ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIGITALIS; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; FLECAINIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; ORAL ANTIDIABETIC AGENT; PROPAFENONE; QUINIDINE; SOTALOL; THYROID HORMONE; VERAPAMIL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL PRACTICE; COMORBIDITY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG INDICATION; ELECTROCARDIOGRAM; FAMILY HISTORY; FEMALE; GERMANY; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL DECISION MAKING; OUTPATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SICK SINUS SYNDROME; STROKE; THROMBOEMBOLISM; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE;

ABLATION TECHNIQUES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY; ELECTRIC COUNTERSHOCK; FEMALE; GERMANY; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; STROKE; YOUNG ADULT;

EID: 65249163311     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun369     Document Type: Article

References (35)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
2. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049-56.
3. Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 2002;155:819- 26.
4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370- 5.
5. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL et al. ACC/AHA/ ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001;22:1852-923.
6. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation- executive summary. Eur Heart J 2006;27:1979-2030.
7. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl): 429S-456S.
8. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrom-botic therapy in atrial fibrillation. Chest 2001;119(Suppl 1):194S-206S.
9. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999;99: 3028-35.
10. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34.
11. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005;149:489-96.
12. Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J 2006;152:1097-103.
13. Reynolds MR, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006;97:538-43.
14. Carlsson J, Tebbe U, Rox J, Harmjanz D, Haerten K, Neuhaus KL et al. Cardioversion of atrial fibrillation in the elderly. ALKK-Study Group. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausaerzte. Am J Cardiol 1996;78:1380-4.
15. Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997;47:285-9.
16. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001;22:1954-9.
17. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-6.
18. Gallagher MM, Camm J. Classification of atrial fibrillation. Am J Cardiol 1998;82: 18N-28N.
19. Haissaguerre M, Sanders P, Hocini M, Takahashi Y, Rotter M, Sacher F et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. J Cardiovasc Electrophysiol 2005;16:1125-37.
20. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
21. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9.
22. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669-74.
23. Murgatroyd FD, Camm AJ. Atrial arrhythmias. Lancet 1993;341:1317-22.
24. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
25. van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
26. Testa L, Biondi-Zoccai GG, Dello RA, Bellocci F, Andreotti F, Crea F. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005;26:2000-6.
27. Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002;360:1275-9.
28. Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000;101: 1282-7.
29. Fisher JD, Spinelli MA, Mookherjee D, Krumerman AK, Palma EC. Atrial fibrillation ablation: reaching the mainstream. Pacing Clin Electrophysiol 2006;29: 523-37.
30. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
31. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
32. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
33. Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005;46:1729-36.
34. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47.
35. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.